Detail akcie Medicenna Therap Rg online

Business Summary: Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.
Financial Summary: BRIEF: For the nine months ended 31 December 2025, Medicenna Therapeutics Corp revenues was not reported. Net loss increased 9% to C$14.2M. Higher net loss reflects Research and development - Balancing val increase of 35% to C$10.1M (expense), Foreign exchange (gain) loss decrease from C$1M (income) to C$829K (expense), Finance income decrease of 56% to C$476K (income).